Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27696829 | 0.89 | HDAC1 (0.47) | HDAC1KCNK3HDAC2HDAC3SNCA | |
| SCHEMBL2274754 | 0.87 | HDAC2 (0.53) | HDAC1HDAC2HDAC3ACLYKDM4E | |
| SCHEMBL2273488 | 0.86 | SUCNR1 (0.52) | HDAC1HDAC2HDAC3ACLYMEN1 | |
| SCHEMBL12117779 | 0.86 | HDAC1 (0.43) | HDAC1HDAC2HDAC3ACLYMEN1 | |
| SCHEMBL12117782 | 0.86 | HDAC1 (0.46) | HDAC1HDAC2ACLYKDM4E | |
| SCHEMBL2269847 | 0.85 | HDAC2 (0.52) | HDAC1HDAC2HDAC3ACLYKDM4E | |
| Cyanate SCHEMBL27830146 | 0.85 | HDAC2 (0.51) | HDAC1HDAC2HDAC3ACLYKDM4E | |
| SCHEMBL12117775 | 0.85 | HDAC1 (0.43) | HDAC1ACLYMEN1MAPTKMT2A | |
| SCHEMBL1317575 | 0.85 | HDAC1 (0.47) | HDAC1HDAC2HDAC3ACLYKDM4E | |
| SCHEMBL2270236 | 0.85 | ACLY (0.61) | HDAC1KCNK3HDAC2HDAC3SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | HDAC1 71/4885KCNK3 3311/4885HDAC2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.